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Abstract
The balance between T helper (Th) 1 and Th2 cell responses is a major determinant of the outcome of experimental
leishmaniasis, but polarized Th1 or Th2 responses are not sufficient to account for healing or nonhealing. Here we show that
high arginase activity, a hallmark of nonhealing disease, is primarily expressed locally at the site of pathology. The high
arginase activity causes local depletion of L-arginine, which impairs the capacity of T cells in the lesion to proliferate and to
produce interferon-c, while T cells in the local draining lymph nodes respond normally. Healing, induced by chemotherapy,
resulted in control of arginase activity and reversal of local immunosuppression. Moreover, competitive inhibition of
arginase as well as supplementation with L-arginine restored T cell effector functions and reduced pathology and parasite
growth at the site of lesions. These results demonstrate that in nonhealing leishmaniasis, arginase-induced L-arginine
depletion results in impaired T cell responses. Our results identify a novel mechanism in leishmaniasis that contributes to
the failure to heal persistent lesions and suggest new approaches to therapy.
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Introduction
The leishmaniases, a group of vector-borne parasitic diseases,
represent a major public health problem worldwide. Currently,
the diseases affect an estimated 12 million people in 88 countries,
and approximately 350 million people are at risk. Leishmaniases
present with a wide range of symptoms, ranging from the self
healing cutaneous form, which produces skin ulcers; to the
mucocutaneous form, which leads to the destruction of mucous
membranes of the mouth, throat, nose and neighbouring tissue; to
the visceral form, the most severe form of leishmaniasis, in which
the mortality rate can be as high at 100%. The leishmaniases
belong to the most neglected tropical diseases, affecting the poorest
populations, for whom access to diagnosis and effective treatment
are most difficult. Much effort has been put into the discovery of
new drugs for the treatment of this pathology, but still the most
widely used drugs remain the pentavalent antimonials, which were
introduced 50 years ago. However, these drugs have many
limitations, such as the long course of treatment, severe side effects
and development of resistance. No efficient vaccine is available to
date (http://www.who.int/leishmaniasis/en/).
In all forms of leishmaniasis, both immunity and pathology are
predominantly mediated by T lymphocytes. Experimental studies
in inbred strains of mice with Leishmania (L.) major have established
the current paradigm of T helper (Th) cell subset involvement in
infectious diseases. In this paradigm, control of infection and
healing have been associated with a polarized Th1 response
whereas non-healing has been ascribed to an interleukin (IL)-4-
dominated polarized Th2 response [1,2]. However, the regulation
of immune responses against Leishmania parasites is complex and
Th2 dominance does not fully explain nonhealing [3,4].
Furthermore, in human leishmaniasis, the different clinical
outcomes do not appear to be solely associated with Th1- or
Th2-type responses. Indeed, whereas IL-4 has been shown to be
higher in the plasma of patients with visceral leishmaniasis (VL)
[5,6], several proinflammatory cytokines such as IL-1, IL-6, IL-12,
interferon(IFN)-c and tumor necrosis factor(TNF)-a are also
elevated [7,8].
One of the main immunological features of the active form of
visceral [9,10,11] and nonhealing cutaneous leishmaniasis (CL)
[12] is a pronounced immunosuppression, as shown by the
inability of peripheral blood mononuclear cells (PBMCs) to
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proliferate and produce IFN-c in response to antigenic challenge.
The mechanisms leading to this suppression are not fully identified
and it is not clear whether there are a cause or a consequence of
nonhealing disease.
Leishmania are obligate intracellular parasites in their mamma-
lian host: they survive and replicate predominantly in macro-
phages. Depending on the balance of two inducible enzymes,
nitric oxide synthase 2 (iNOS) and arginase, macrophages can
either kill parasites or support their growth. These two enzymes
use a common substrate, L-arginine, and are competitively
regulated by type 1 and type 2 cytokines [13,14]. The type 1
cytokine, IFN-c, induces classical activation of macrophages and
expression of iNOS that in turn oxidizes L-arginine in a two-step
process into nitric oxide (NO) - a metabolite responsible for
parasite killing. The key type 2 cytokine, IL-4, results in alternative
activation of macrophages and the induction of arginase that
hydrolyzes L-arginine to urea and ornithine. The latter is the main
intracellular source for the synthesis of polyamines, which are
necessary for parasite growth [15].
The metabolism of L-arginine by arginase is emerging as a
crucial mechanism for the regulation of immune responses.
Arginase 1 has been shown to impair T cell responses by reducing
the bioavailability of L-arginine: high arginase activity expressed
by myeloid cells results in increased uptake and hydrolysis of
extracellular L-arginine into the cells, thereby causing a reduction
of L-arginine levels in the microenvironment. In turn, this
decrease in L-arginine results in T cell hyporesponsiveness
[16,17,18,19,20,21,22,23]. This T cell dysfunction is directly
attributed to L-arginine starvation, arresting cells in the G0-G1
phase [19]. Arginase-mediated L-arginine deprivation has been
shown to cause T cell hyporesponsiveness in a variety of
pathological and physiological responses [22,24,25]. High arginase
expression has been associated with a variety of diseases such as
chronic inflammation [23], asthma [26], psoriasis [27] and
infectious diseases [15,28,29,30].
We and others have recently shown that in vivo uncontrolled
replication of Leishmania parasites at the site of pathology in
nonhealing BALB/c mice correlates with abnormally high levels of
arginase activity [15,31]. In the present study we tested the
hypothesis that excessive arginase activity at the site of pathology
contributes to persistent nonhealing leishmaniasis by causing local
suppression of T cell responses.
Methods
Mice
6–8 week old female BALB/c and CBA mice (Charles River,
UK) were kept in individually vented cages. Animal colonies,
screened regularly for mouse pathogens, consistently tested
negative. Animal experiments were performed in accordance with
Home Office and institutional guidelines.
Experimental infection with L. major parasites
For infections, 26106 stationary phase L. major LV39 (MRHO/
SU/59/P-strain) promastigotes or 16105 metacyclic L. major LV39
(MRHO/SU/59/P-strain) isolated as described in [32] were
injected subcutaneously (s.c.) into the footpad, and lesions
monitored as described [33].
Nanometer-scale, apolipoprotein-stabilised phospholipid bilayer
disk complexes (nanodisks; ND) harboring amphotericin B (AMB)
[34,35] were injected intraperitoneally (i.p.) in L. major infected
BALB/c mice at a concentration of 5 mg/kg (as AMB) on days 1,
2, 7, 14, 21 and 28 post infection.
To inhibit arginase in vivo, mice were treated i.p. daily, starting
on the day of infection and throughout the course of infection with
1 mg of Nv-hydroxy-nor-L-arginine (nor-NOHA, Bachem, Bu-
bendorf, Switzerland) in 0.1 ml of PBS.
L-arginine (L-arginine-monohydrochloride, Roth) was injected
i.p. at a concentration of 10 mg/100 ml, three times a week,
starting on day 15 post infection.
Determination of parasite load
The number of living L. major parasites in infected tissues was
determined using a parasite limiting dilution assay as described
[33].
Determination of arginase activity
Arginase activity was determined using 25 ml of tissue
homogenate, as described [15]. Briefly, 25 ml of tissue homogenate
was solubilized with 25 ml of a solution containing 0.1% Triton X-
100/10 mM MnCl2/25 mM Tris-HCl and the enzyme was
activated by heating for 10 min at 56uC. Arginine hydrolysis
was achieved by incubating the lysate with 50 ml of 0.5 M L-
arginine (pH 9.7) at 37uC for 15–120 min. The reaction was
stopped with 400 ml of H2SO4 (96%)/H3PO4 (85%)/H2O (1/3/7,
v/v/v). Urea concentration was measured at 550 nm after
addition of 20 ml a-isonitrosopropiophenone (dissolved in 100%
ethanol), followed by heating at 100uC for 45 min. One unit of
enzyme activity is defined as the amount of enzyme that catalyzes
the formation of 1 mmol of urea per min.
Amastigotes were purified from the lesions as described in [36]
and arginase activity was measured as described above
Determination of L-arginine concentration
Single cell suspensions from individual footpads and popliteal
lymph nodes were prepared in 500 ml PBS on cell dissociation
sieves. Suspensions were centrifuged 5 min at 1600 rpm and cell-
free supernatants were centrifuged further at 14000 rpm for
10 min. The supernatants were frozen for further use.
Cell-free supernatants were prepared for amino acid analysis by
deproteinisation using sulphosalicylic acid; cell-free supernatants
were filtered using VectaSpin Micro 0.45 mm filters (Whatman
International Ltd.). Free amino acids were separated by ion-
exchange chromatography and quantified by postcolumn ninhy-
drin derivatisation using an amino acid analyser (AminoTac JLC-
500/V). An internal standard, S-(2-aminoethyl)-L-cysteine hydro-
Author Summary
Leishmania parasites are obligate intracellular pathogens
that predominantly invade macrophages. Instruction of
macrophages by T cell-derived signals is required to
control parasite growth. Here we show that arginase, an
enzyme induced in Leishmania-infected macrophages, is
highly expressed at the site of pathology in nonhealing
lesions and causes local depletion of L-arginine, an amino
acid that is essential for efficient T cell responses. This local
reduction in L-arginine impairs the capacity of T cells in the
lesion to proliferate and to produce interferon-c, one of
the signals required for parasite killing. Cure of Leishmania
infection by drug treatment is accompanied by a reduction
in arginase activity and restoration of T cell effector
functions. Furthermore, inhibition of arginase, as well as
injection of L-arginine, reverses immunosuppression and
results in more efficient control of parasite replication. Our
results identify a novel mechanism accounting for
ineffective T cell responses in nonhealing leishmaniasis.
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chloride and amino acid standard solutions (basics; acidics and
neutrals) were supplied by Sigma.
To test the possibility that L-arginine could be metabolised by
arginase during the preparation of the cell-free supernatants, we
measured the level of urea produced in the presence or in the
absence of exogenous L-arginine in footpad extracts from 4 week
infected BALB/c mice. Following a two-hour incubation on ice,
we measured 6.260.2 mg urea in the presence of exogenous L-
arginine and 6.060.3 mg urea in the absence of L-arginine. These
results show that L-arginine is not hydrolyzed during the
preparation of the footpad extracts.
Proliferation assay
L. major infected mice were treated with 1 mg bromodeoxyur-
idine (BrdU) (Sigma) i.p. once a day for the last four days before
experiments were terminated. Draining lymph nodes from
individual mice or footpads (pool of at least 2 footpads) were
homogenised into single cell suspensions using cell dissociation
sieves and the frequencies of CD4+BrdU+ T cells were determined
directly ex vivo. Before surface labeling with anti-CD4 mAb (clone
H129.19 or GK1.5, Pharmingen), cells were preincubated with
1 mg of rat anti-mouse monoclonal antibody CD32/CD16 (FccII/
III receptor, Pharmingen). Cells were washed, fixed and
permeabilized using the method described in [37]. Detection of
CD4+ BrdU+ cells was performed using a FACSCalibur (Becton
Dickinson) and data were analyzed using Summit v4.3 software.
Intracellular cytokine determination
Draining lymph nodes from individual mice or footpads (pool of
at least 2 footpads) were prepared as described above. Cells
(16106) were stimulated with 50 ng of phorbol 12-myristate 13-
acetate (PMA; Sigma) and 500 ng of ionomycin (Calbiochem) or,
as a control, in the presence of complete medium alone for 4 h,
with 10 mg of brefeldin A (Sigma) added for the last 2 h. Before
surface labeling with anti-CD4 mAb (clone H129.19 or GK1.5,
Pharmingen), cells were preincubated with 1 mg of rat anti-mouse
monoclonal antibody CD32/CD16 (FccII/III receptor, Pharmin-
gen). Cells were washed, fixed and permeabilized as described in
[38] before the anti-cytokine antibodies or the isotype controls
were added (anti-IL-4 mAb, clone BVD4-1D11; anti-IFN-c mAb,
clone XMG1.2; anti-IL-10 mAb, clone JES5-16E3; appropriately
labeled rat immunoglobulin (Pharmingen)). Detection of intracel-
lular cytokines was performed using a FACSCalibur (Becton
Dickinson) and data were analyzed using Summit v4.3 software.
Statistical analyses
Statistical differences were determined using a two-tailed Mann-
Whitney test and differences were considered statistically signifi-
cant at P,0.05.
Results
High levels of arginase activity are restricted to the site of
pathology
In the experimental model of infection with L. major, parasite
growth and pathology occur mainly at the site of infection, that is,
in the footpads. Healer strains, such as CBA mice, develop small
lesions at the site of infection, which heal spontaneously within a
few weeks; by contrast, BALB/c mice, the prototypic nonhealer
strain of mice, develop progressive nonhealing lesions. We have
recently shown that arginase activity is significantly higher at the
site of pathology in infected nonhealer BALB/c mice than in
healer CBA mice [15]. Here, we extend these results and show
that the expression of high arginase activity is restricted to the site
of parasite growth and pathology, the infected footpads: in
nonhealer mice, arginase activities were significantly higher in the
lesions than in the lymph nodes draining the lesions (Figures 1A).
In healer mice, low arginase activity was exclusively detectable in
the footpads and was below the detection limit in the draining
lymph nodes (Figure 1A). Arginase was below the detection limit in
the spleen of both groups of mice and was not detectable in the
contralateral non-infected footpad (data not illustrated). To
account for the differences in organ sizes, we also determined
arginase activity as mU/mg of protein and found similar
tendencies as those in Figure 1 (data not illustrated).
We and others have shown that Leishmania parasites express
their own arginase [39,40]. We have already shown by enzymatic
assay, Western blot and PCR that in the lesions of mice infected
with L. major, as well as in infected bone marrow derived
macrophages, arginase activity measured was mainly of host
origin [15,41]. To support these results further, we measured
arginase in the lesions of BALB/c mice four weeks post infection,
as well as in amastigotes purified from the lesions. Arginase activity
was detectable in amastigotes (2.660.2 U/lesion), however, there
was a 80.4-fold higher arginase expression in the lesions
(209.2612.8 U/lesion, data not shown), further confirming that
the majority of arginase activity measured in the lesion is host
arginase.
Next, we measured the levels of arginase activity in the lesions of
BALB/c and CBA mice following infection with metacyclic L.
major parasites [32]. As shown in Table 1, arginase activity is
significantly higher at the site of pathology in infected BALB/c
mice than in CBA mice.
The results presented in Figure 1A show that high arginase
activity is a hallmark of nonhealing disease and is localised at the
site of pathology.
High arginase activity at the local site of pathology
induces depletion of L-arginine in the microenvironment
We and others have shown that induction of arginase in myeloid
cells rapidly results in the depletion of L-arginine in the culture
medium [15,18,23]. Moreover, higher arginase activity measured
in PBMCs from patients suffering from tuberculosis [30] and
asthma [42] coincides with lower levels of L-arginine in the
plasma. In these studies, the levels of arginase activity and L-
arginine were measured in the circulation, but not at the site of
pathology. We wished to test the hypothesis that the high levels of
arginase activity present in the lesions of nonhealing mice might
result in local depletion of L-arginine from the extracellular milieu.
We therefore measured the levels of L-arginine in the draining
lymph nodes and lesions of L. major-infected healer and nonhealer
mice. As shown in Figure 1B (upper panel), there was a small non-
significant decrease in the levels of L-arginine in the extracts from
draining lymph nodes of nonhealer mice 4 weeks post infection
(12.563.4 vs 10.061.4 nmol/lymph nodes extract, P.0.05). In
sharp contrast, the levels of L-arginine were found to be
significantly lower in the lesion extracts of nonhealer mice than
in healer mice (1.860.5 vs 15.162.5 nmol/footpad extract,
P,0.05, Figure 1B, lower left panel). Consistent with this observed
decrease in L-arginine concentrations in nonhealer lesions, we
observed an increase in the levels of ornithine, one of the products
of arginase-mediated L-arginine catabolism, in these lesions
(Figure 1B, lower right panel). Similar results were obtained with
lesions from healer and nonhealer mice 2 weeks post infection
(data not illustrated). The levels of L-arginine found in the footpad
extracts of non-infected healer and nonhealer mice were 22.062.1
and 18.564.4 nmol/footpad extract respectively (P.0.05, data
not illustrated).
Arginase and T Cell Responses in Leishmaniasis
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Figure 1. High arginase activity is localised at the site of pathology and results in reduced levels of L-arginine at the site of
pathology. (A) Groups of BALB/c and CBA mice (n = 4) were infected with L. major parasites in one hind footpad and 1, 4 and 6 weeks post infection,
individual footpads and popliteal lymph nodes were harvested and arginase activity was determined by enzymatic assay. Each symbol represents
arginase activity for one individual organ, the horizontal line representing the average value. Data show the results of one representative experiment
out of five independent experiments. (B) Groups of BALB/c and CBA mice (n = 4) were infected with L. major parasites in one hind footpad and 4
weeks post infection, individual footpads and popliteal lymph nodes were harvested and levels of extracellular L-arginine were determined using an
amino acid analyser. Data show the results of one representative experiment out of two independent experiments.
doi:10.1371/journal.pntd.0000480.g001
Arginase and T Cell Responses in Leishmaniasis
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Since we cannot evaluate the volume of extra-cellular fluid in the
lymph nodes and footpads, we also expressed the levels of L-
arginine as a percentage of the combined concentrations (%L-
arginine) of the ten essential amino acids (arginine, valine, histidine,
isoleucine, leucine, lysine, methionine, phenylalanine, tryptophan
and threonine,). Using this approach, we obtained similar results as
those presented in Figure 1B. That is, a small reduction in %L-
arginine was found in the draining lymph nodes of nonhealer mice
as compared to healer mice (8.861.9% vs 13.960.9%, P,0.05,
data not illustrated), whereas %L-arginine was considerably lower
in the footpads of nonhealer mice as compared to healer mice
(0.460.1% vs 8.661.6%, P,0.05, data not illustrated).
These results show that the high levels of arginase activity
present at the site of pathology results in the depletion of L-
arginine from the microenvironment.
Depletion of L-arginine coincides with impaired
proliferation of effector CD4+ T cells at the site of
pathology
We then assessed the impact of the reduced levels of L-arginine
in the lesions on local T cell responses: we hypothesized that, in
the lesions of nonhealer mice, high arginase activity and the
consequent low level of L-arginine (Figures 1A and B) result in
impairment of T cell responses, whereas the T cell responses are
unaffected in the draining lymph nodes where arginase activity
was low or undetectable (Figures 1A). To test this hypothesis, we
first measured the proliferation of L. major-specific CD4+ T cells in
vivo by quantifying the frequency of CD4+ T cells that had
incorporated BrdU in vivo, in cells isolated from the draining lymph
nodes and the lesions, without any further restimulation. We found
that, two weeks post infection, there was a small and non-
significant increase in the frequency of proliferating CD4+ T cells
in the draining lymph nodes of healer mice compared with
nonhealer mice (1.0560.2% vs 0.7660.2%, P.0.05, Figures 2A).
However, at the site of pathology, the frequency of CD4+BrdU+ T
cells was significantly greater in healer mice than in nonhealer
mice (1.5560.1% vs 0.6360.2%, P,0.05) (Figures 2A). Similarly,
the frequency of proliferating CD4+ T cells was significantly
greater in the lesions of healer mice than in nonhealer mice 4
weeks post infection (Figure 2B, 3.060.6% vs 0.660.1%, P,0.05);
in contrast the frequency of proliferating CD4+ T cells in the
lymph nodes did not differ between the two strains 2 and 4 weeks
post infection (Figure 2A and B). These results show that when
measured directly ex vivo, the frequency of proliferating CD4+ T
cells in the draining lymph nodes in vivo was similar in healer and
nonhealer strains of mice. In sharp contrast, the in vivo frequency of
proliferating CD4+ T cells was significantly lower in the lesions of
nonhealer mice than in those of healer mice.
It is unlikely that the impaired proliferation observed in the
lesions of nonhealer mice is due to different abilities of lymphocytes
to migrate to the lesions. Indeed, cells migrate even more efficiently
in nonhealer BALB/c mice as shown by a significantly increased cell
infiltration in their lesions compared to healer CBA mice
(132696104 vs 80656104 cells/lesions, data not illustated). This
represents 4.86104 CD4+ T cells in the lesions of BALB/c mice as
compared to 3.26104 in CBA mice. These results show that there is
a higher frequency of CD4+ T cells migrating to the lesions in
nonhealer mice and therefore show that the migration of CD4+ T
cells to the lesions is not impaired in BALB/c mice.
Of note, whereas there are more CD4+BrdU+ T cells in the
draining lymph node as compared to the footpads (Figure 2A), the
frequency of proliferating CD4+ T cells is clearly higher in the
footpad: indeed, 16.7% of CD4+ T cells (0.6% of 3.6%) are
proliferating in the lesions of BALB/c mice as compared to 2.9%
(0.8% of 26.9%) in the draining lymph nodes; in CBA mice, 40%
of CD4+ T cells in the lesions are BrdU+ (1.6% of 4%) vs 2.7% in
the draining lymph nodes (1.1% of 40.2%).
The results presented in Figures 1 and 2 show that high arginase
activity at the local site of infection and the subsequent low L-
arginine levels in nonhealer mice are accompanied by reduced
proliferation of CD4+ T cells in the lesion.
Depletion of L-arginine is associated with impaired
cytokine production by effector CD4+ T cells at the site of
pathology
Cytokines play an important role in both the healing and the
nonhealing forms of experimental leishmaniasis. Therefore, we
investigated the frequency of L. major-specific IFN-c+, IL-4+ and
IL-10+ CD4+ T cells directly ex vivo, both in the draining lymph
nodes and in the lesions of infected nonhealer (BALB/c) and
healer (CBA) mice. As shown in Figures 3A and B, CD4+IFN-c+ T
cells were detectable in the lymph nodes draining the lesions in
both strains of mice, with a small increase in the frequency of
CD4+IFN-c+ T cells in healer mice (1.760.3% vs 1.260.1%,
P,0.05). CD4+IL-4+ T cells were detectable in the draining lymph
nodes of nonhealer mice, but not in healer mice, and IL-10 was
below the detection limit in both groups. Although no intracellular
IL-4 or IL-10 was detectable in the lesions of either BALB/c or
CBA mice, CD4+ IFN-c+ T cells were detectable in the lesions of
L. major-infected mice from both nonhealer and healer strains
(Figures 3A and B). However, there was a markedly higher
frequency of CD4+IFN-c+ T cells in the lesions of healer than
nonhealer mice (3.960.5% vs 1.160.2%, P,0.05). Similar results
were obtained 4 weeks post infection (Figure 3C).
These results show that antigen-specific CD4+ T cells at the site
of pathology in nonhealing lesions have an impaired capacity to
express IFN-c, whereas this response is only mildly affected in the
draining lymph nodes.
We conclude that high arginase activity at the local site of
infection and the consequent low L-arginine levels in nonhealer
mice are associated with an impaired capacity of CD4+ T cells to
produce IFN-c.
Cure of nonhealing leishmaniasis correlates with
downregulation of arginase activity and restoration of
CD4+ T cell responses
As a further test of the hypothesis that high arginase activity
correlates with local immunosuppression and to test the prediction
Table 1. Infection with metacyclic L. major parasites results in
significantly higher arginase activity in the lesions of BALB/c
mice than CBA mice.
Arginase activity (mU/mg
protein) BALB/c CBA
Day 7 1,521.8689.2 452.1623.9
Day 28 452,363.0622,421.3 221.969.5
Day 42 426,978.6619,125.3 198.665.6
Groups of BALB/c and CBA (n = 4) mice were infected with metacyclic L. major
parasites in one hind footpad and 1, 4 and 6 weeks post infection, individual
footpads were harvested and arginase activity was determined by enzymatic
assay. Values given are the average arginase activity 6standard deviation. Data
show the results of one representative experiment out of three independent
experiments.
doi:10.1371/journal.pntd.0000480.t001
Arginase and T Cell Responses in Leishmaniasis
www.plosntds.org 5 July 2009 | Volume 3 | Issue 7 | e480
that downregulation of arginase correlates with restoration of
effector responses, we investigated T cell functions in BALB/c
mice that were chemotherapeutically treated to control the
infection. This model would also exclude any contribution of
genetic factors that might cause the different outcomes of disease
in different strains of mice.
In this study, we used a novel lipid formulation of the macrolide
polyene antibiotic, amphotericin B (AMB) [34]. Recent studies
have shown that nanoscale, discoidal particles of reconstituted
high-density lipoprotein, enriched with AMB (termed nanodisks
(ND)) induce clearance of L. major infection in BALB/c mice [35].
As shown here in Figure 4A, AMB-ND-treated mice developed
only minor lesions 5 weeks post infection, whereas untreated L.
major-infected BALB/c mice developed ulcerated lesions that
contained .400-fold more parasites (P,0.05). Significantly lower
arginase activity was observed in the lesions of AMB-ND-treated
BALB/c mice (Figure 4A, P,0.05), confirming further that low
arginase expression correlates with control of parasite replication
[15].
To assess whether low arginase activity in the lesions of healed
BALB/c mice was associated with restored immune effector
functions, we isolated both lesions and draining lymph nodes from
AMB-ND treated and control infected BALB/c mice and
measured the capacity of CD4+ T cells to proliferate and express
IFN-c directly ex vivo. We found that CD4+ T cells from draining
lymph nodes from both groups of mice had a similar capacity to
Figure 2. Impaired proliferation of antigen-specific CD4+ T cells. Groups of BALB/c and CBA mice (n = 8) were infected with L. major parasites
for two (A) or four (B) weeks and were injected with 1 mg BrdU daily for 4 days. Individual popliteal lymph nodes and footpads (pool from at least
two footpads) were harvested and the % of proliferating CD4+ T cells was determined by flow cytometry. (2A) left panels: dot plot profiles of
CD4+BrdU+ T cells 2 weeks post infection; right panels: % of CD4+ BrdU+ T cells 2 weeks post infection. (2B) % of CD4+ BrdU+ T cells 4 weeks post
infection. Error bars represent standard deviations. Isotype control: 0.27%. Data show the results of one representative experiment out of three
independent experiments.
doi:10.1371/journal.pntd.0000480.g002
Arginase and T Cell Responses in Leishmaniasis
www.plosntds.org 6 July 2009 | Volume 3 | Issue 7 | e480
proliferate and express IFN-c (Figure 4B). In contrast, there was a
significant increase in the capacity of CD4+ T cells from the lesions
of BALB/c mice treated with AMB-ND both to proliferate and
express IFN-c (Figure 4B).
The results presented in Figure 4 show that healing is associated
with a significant reduction in arginase activity at the site of
pathology and with restoration of efficient CD4+ T cell effector
functions in vivo.
Interfering with L-arginine metabolism restores CD4+ T
cell responses at the site of pathology
To demonstrate further that arginase-induced L-arginine
depletion results in impaired T cell responses at the site of
pathology, we treated L. major-infected nonhealer BALB/c mice
with a competitive inhibitor of arginase, Nv-hydroxy-nor-L-
arginine (nor-NOHA) [15]. Two weeks of treatment with nor-
NOHA resulted in non-significant differences in lesion size
(1.460.2 vs. 1.260.1 mm, P.0.05, data not shown) and arginase
activity (16.862.9 vs 16.064.9 mU/footpad, P.0.05, data not
illustrated) and significantly reduced parasite load at the site of
pathology (Figure 5A, P,0.05). We can exclude the possibility that
nor-NOHA is responsible for the lower parasite load as we have
show previously that it does not affect parasite growth [15].
Importantly, the proliferation and production of IFN-c by CD4+
T cells was significantly higher in lesions of mice that were treated
with the competitive inhibitor of arginase (P,0.05, Figure 5A). No
differences were observed in the draining lymph nodes (Figure 5A).
These results show that in vivo inhibition of arginase activity
restores CD4+ T cell responses at the site of pathology.
Finally, to demonstrate unequivocally that L-arginine depletion
at the site of pathology is responsible for T cell hyporesponsive-
ness, BALB/c mice were treated with L-arginine starting from day
10 post infection. As shown in Figure 5B, five weeks post infection,
BALB/c mice treated with L-arginine develop significantly smaller
lesions and harbour less parasites in their lesions as compared to
the untreated group. Arginase activity was lower in the treated
group than in the untreated group (165641 vs 194626 U/
footpad respectively, P.0.05, data not illustrated). To determine
whether treatment with L-arginine supplementation restores T cell
responses, we measured proliferation and IFN-c production by
CD4+ T cells in the draining lymph nodes and in the lesions. We
found that there was a significant increase in the capacity of CD4+
Figure 3. Impaired capacity of antigen-specific CD4+ T cells to express cytokines. Groups of BALB/c and CBA mice (n = 8) were infected
with L. major parasites for two (A and B) or four (C) weeks. Individual popliteal lymph nodes and footpads (pool from at least two footpads) were
harvested and the % of cytokine-expressing CD4+ T cells was determined by flow cytometry. (3A) dot plot profiles of cytokine-expressing CD4+ T cells
isolated from the popliteal lymph nodes and the footpads two weeks post infection; (3B) % of cytokine-expressing CD4+ T cells two weeks post
infection. (3C) % of cytokine-expressing CD4+ T cells four weeks post infection. Error bars represent standard deviations. Isotype control for IFN-c:
0.2360.05%, IL-4: 0.3160.08% and IL-10: 0.2660.06%. All cytokines were below the detection limit when the cells were stimulated in the absence of
PMA/ionomycin stimulation. The detection limits were defined as % isotype control +3 standard deviations: IFN-c= 0.38%, IL-4 = 0.55% and IL-
10 = 0.44%. Data show the results of one representative experiment out of three independent experiments.
doi:10.1371/journal.pntd.0000480.g003
Arginase and T Cell Responses in Leishmaniasis
www.plosntds.org 7 July 2009 | Volume 3 | Issue 7 | e480
T cells from the lesions of BALB/c mice treated with L-arginine
both to proliferate and express IFN-c as compared to the
untreated group (Figure 5C). CD4+ T cells from draining lymph
nodes from the control group of mice and that treated with L-
arginine had a similar capacity to proliferate and express IFN-c
(Figures 5C).
These results show that treatment of nonhealer BALB/c mice
with L-arginine restores CD4+ T cell effector functions at the site
of pathology.
Discussion
One of the main immunological characteristics of the active
form of visceral leishmaniasis is the inability of peripheral blood
mononuclear cells to mount an efficient immune response, as
shown by their impaired capacity to proliferate or produce IFN-c
in response to Leishmania antigen in vitro [9,10,11,43]. PBMCs from
patients with recurrent cutaneous infections also produce lower
levels of IFN-c than those from patients with active lesions or
patients who had recovered [44]. PBMCs isolated from patients
with diffuse cutaneous leishmaniasis are hyporesponsive to
antigenic restimulation [12,45,46]. In sharp contrast, PBMCs
from patients affected by the self-healing form of cutaneous
leishmaniasis proliferate and produce IFN-c when stimulated with
Leishmania antigen [44,47,48]. The general picture emerging from
the studies described above is that immunosuppression is a
hallmark of nonhealing forms of cutaneous and visceral leishman-
iasis. However, the molecular mechanisms responsible for
immunosuppression in the nonhealing form of leishmaniasis are
not understood.
The ability of T cells to proliferate and produce cytokines in
response to antigenic challenge has been shown by restimulating
PBMCs with Leishmania antigens in vitro. Similarly, in the mouse
models of both cutaneous and visceral leishmaniasis, immune
responses have mostly been evaluated by restimulating lymph
node or spleen cells with Leishmania antigen in vitro. By assaying the
effector functions of antigen-specific CD4+ T cells isolated from
the site of pathology, without further restimulation, we show here
that CD4+ T cells isolated from the lesions of nonhealer BALB/c
mice proliferate at a significantly lower rate than those from self-
healing CBA or BALB/c mice cured chemotherapeutically. CD4+
T cells isolated from diseased mice also have an impaired ability to
express IFN-c. These results substantiate the observation made in
the different forms of nonhealing leishmaniasis in humans, that
severe disease is associated with inefficient immune responses. Our
results suggest a mechanism for the observed impaired immune
responses in leishmaniasis: in the lesions, local depletion of L-
arginine by arginase impairs the ability of T cells to mount an
effective response.
L-arginine depletion by arginase-expressing myeloid cells has
been shown previously in vitro [15,23,49,50]; and a correlation
between high arginase activity and reduced levels of L-arginine has
been shown in the plasma of patients suffering from active
tuberculosis [30]. Arginase-mediated L-arginine deprivation has
Figure 4. Control of disease in BALB/c mice correlates with downregulation of arginase and restoration of immune responses. Two
groups of BALB/c mice (n = 5) were infected with L. major parasites in one hind footpad and one group was injected i.p. with 5 mg/kg of AMB-ND on
day 1, 2, 7, 14, 21 and 28. (A) The lesion development was monitored at weekly intervals and five weeks post infection, number of viable parasites and
the arginase activity was measured in individual footpads. (B) % of CD4+ BrdU+ T and % of IFN-c-expressing CD4+ T cells in individual popliteal lymph
nodes and lesions (pool of at least 2 footpads), error bars represent standard deviations. Data show the results of one representative experiment out
of two independent experiments.
doi:10.1371/journal.pntd.0000480.g004
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been shown to cause T cell hyporesponsiveness in both
pathological and physiological responses [22,24,25,51]. Further,
diseases such as chronic inflammation [23], asthma [26], psoriasis
[27] and certain infectious diseases such as schistosomiasis [28],
trypanosomiasis [29], leishmaniasis [15] and tuberculosis [30]
have been associated with increased arginase activity. However,
the effects of high arginase activity on the bioavailability of L-
arginine were not studied at the local site of pathology. Here, we
show that L-arginine is depleted from the microenvironment at the
site of pathology and that this low level of L-arginine results in
local immunosuppression in vivo in nonhealing leishmaniasis. T cell
responses were most strongly impaired at the site of pathology - in
the footpads - whereas only minor downregulation of the immune
response was detected in the draining lymph nodes. In the latter,
arginase levels were low or below the detection limit, and levels of
L-arginine were unaltered. Both the proliferation and the capacity
of CD4+ T cells to express IFN-c were significantly lower in the
lesions of nonhealer mice than in those of healer mice. To confirm
further that this T cell hyporesponsiveness is induced by arginase-
induced L-arginine depletion, we interfered with L-arginine
metabolism in vivo by inhibiting arginase or by supplementing
the mice with L-arginine. In both instances, lesion development
and parasite load were reduced and CD4+ T cell responses were
restored at the site of pathology. Therefore, we conclude that
nonhealing lesions and uncontrolled parasite growth are caused by
arginase-mediated L-arginine depletion, which in turn impairs
proliferation and prevents CD4+ T cells from expressing IFN-c
and inducing efficient killing of intracellular parasites in macro-
phages.
It is well established that Leishmania parasites express arginase
[15,39,40]. Although our previous work as well as the data
presented here show that the majority of arginase detected in
Figure 5. Interfering with arginase-induced L-arginine metabolism restores CD4+ T cell responses in nonhealer BALB/c mice. (A) Two
groups of BALB/c mice (n = 8) were infected with L. major parasites and one group was injected daily i.p. with a competitive inhibitor of arginase (nor-
NOHA, 1 mg/mouse) starting from the day of infection. Two weeks later, the number of viable parasites was measured in individual footpads (left
panel) and the % of CD4+ BrdU+ T cells and IFN-c-expressing CD4+T cells was determined by flow cytometry in popliteal lymph nodes and lesions
(pool of at least 2 footpads). Error bars represent standard deviations. Data show the results of one representative experiment out of two
independent experiments. (B) Two groups of BALB/c mice (n = 8) were infected with L. major parasites in one hind footpad and 2 weeks post
infection, one group was injected i.p. with L-arginine (10 mg/mouse) 3 times a week, for 3 weeks. The lesion development was monitored at weekly
intervals (left panel) and 33 days post infection, number of viable parasites and the arginase activity was measured in individual footpads (right
panel). (C) % of CD4+ BrdU+ T cells and IFN-c-expressing CD4+T cells in popliteal lymph nodes and lesions (pool of at least 2 footpads), error bars
represent standard deviations. Data show the results of one representative experiment out of four independent experiments.
doi:10.1371/journal.pntd.0000480.g005
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cutaneous lesions is host arginase [15,41], it is possible that
parasite arginase also modulates the host response [52].
The results presented here substantiate our previous study,
which showed that competitive inhibition of arginase enables
BALB/c mice to control the lesion development, pathology and
parasite load more efficiently [15]. The mice treated with nor-
NOHA displayed smaller lesion sizes and arginase activities were
lower at the site of pathology, however, differences were not
statistically significant between the treated and untreated groups;
this may be due to the timing as these experiments were performed
for 2 weeks. Further, Holscher et al. also showed that delayed
disease onset in macrophage/neutrophil-specific IL-4R-deficient
mice was accompanied by reduced levels of arginase [53].
Here we show that low levels of IL-4 were detectable in the
draining lymph nodes of L. major-infected BALB/c mice directly ex
vivo and but was below detection limit in the lesions. It is possible
that flow cytometry is not sensitive enough to detect CD4+ T cells
that express low levels of IL-4 and/or in addition, there was a only
a small number of cells in the lesions. Th1 and Th2 responses
associated with healing and nonhealing, respectively [1,2,54], have
been largely defined by measuring cytokine production following
in vitro restimulation of lymphoid cells with Leishmania parasites. We
have recently shown that T helper cell responses are significantly
less polarized when determined ex vivo as compared to those
measured after restimulation in vitro [55]. Notably, the difference in
IL-4 production by CD4+ T cells between nonhealer and healer
mice was 2.0-fold when determined ex vivo and 21.1-fold when
measured following in vitro restimulation [55]. Therefore, whereas
lymphoid cells from nonhealer mice mount a strong IL-4 response
after in vitro restimulation, the production of IL-4 by CD4+ T cells
directly ex vivo is low.
Arginase is an essential enzyme and indeed, arginase knockout
mice die by two weeks of age from hyperammonemia. Therefore,
even though our previous study [15] showed promising results
when targeting arginase activity systemically with a competitive
inhibitor, it is unlikely that inhibition of arginase activity could be
used as an intervention strategy. However, dissecting the
mechanisms responsible for the induction of local arginase is
likely to provide new targets for the control of this pathway.
Towards this end, the dramatic effects of AMB-ND therapy on
lesion size, parasite burden and arginase activity in the nonhealer
strains of mice not only provides a useful experimental system, but
also a potentially viable therapy for treatment of Leishmania
infection. The mechanisms resulting in the control of arginase
activities at the site of pathology following treatment with AMB-
ND are not fully understood. Here we show that efficient control
of parasite replication in the lesions was associated with control of
arginase activity. We have previously shown that infection of
macrophages with L. major parasites strongly synergizes with IL-4
to increase arginase activity [56] and we have shown that the
arginase measured was mainly host arginase [15]. Importantly,
infection of macrophages by L. major alone results in the induction
of arginase [56,15]. Therefore, it is tempting to speculate that in
addition to factors such as cytokines, the parasites themselves act
to induce and maintain arginase expression in macrophages. This
suggests that high expression of arginase activity is dependent on
the viability of the parasites and that to efficiently control arginase,
parasites replication has to be restricted. Treatment with L-
arginine might also be a promising therapeutic avenue. Indeed,
our results show that treatment with L-arginine not only restores
efficient T cell responses, but also improves pathology and
decreases parasite load. It has already been shown that treatment
with L-arginine has a potential role in immunomodulation;
benefits include enhanced T cell functions, increase in macro-
phage cytotoxicity and phagocytosis and accelerated wound
healing potential [57,58,59].
The findings presented here provide a novel mechanism that
explains the incapacity of CD4+ T cells to mount an efficient
response in the nonhealing form of leishmaniasis. Targeting the
metabolism of L-arginine is likely to be an important therapeutic
and prophylactic strategy to treat not only leishmaniasis, but also
other diseases associated with high arginase activity such as cancer,
psoriasis and allergic asthma.
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